Transphorm Q2 Adj EPS $(0.08) Beats $(0.10) Estimate, Sales $5.01M Miss $5.30M Estimate
Portfolio Pulse from bharat@benzinga.com
Transphorm (NASDAQ:TGAN) reported Q2 adjusted EPS of $(0.08), beating the estimate of $(0.10) by 20%. However, the company's sales of $5.01M missed the estimate of $5.30M by 5.47%. The EPS is an 11.11% increase from last year, while sales increased by 36.51% from the same period last year.
November 09, 2023 | 9:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Transphorm's Q2 results showed a mixed performance with EPS beating estimates but sales missing. The YoY increase in both EPS and sales could be seen as a positive sign.
Transphorm's EPS beat estimates, which is a positive sign. However, the company missed on sales, which could be a concern for investors. The YoY increase in both EPS and sales indicates growth, but the missed sales estimate may temper any potential positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100